Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
November 09, 2023 16:05 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
BioTech Breakthrough Awards Badge[1] copy.jpg
Garuda Therapeutics Named “Overall Cell Biology Company of the Year” By BioTech Breakthrough
November 08, 2023 08:03 ET | BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
Whitelogolarge.jpg
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, CELL, CCF, AGE
September 12, 2023 14:01 ET | Monteverde & Associates PC
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
MooreKuehn.jpg
Moore Kuehn Encourages CELL, CCF, IMNM, and KLR Investors to Contact Law Firm
September 11, 2023 10:40 ET | Moore Kuehn
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Whitelogolarge.jpg
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – HCCI, CEQP, CELL, CTG
September 05, 2023 19:34 ET | Monteverde & Associates PC
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Research Nester Logo.jpg
Cast Acrylic Market revenue to reach USD 5 Billion by 2035, says Research Nester
September 05, 2023 07:30 ET | Research Nester
New York, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The global cast acrylic market size is poised to grow at a CAGR of over ~5% from 2023 to 2035. The market is anticipated to garner a revenue of USD 5...
Whitelogolarge.jpg
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, CELL, ESTE, CPRI
August 28, 2023 17:34 ET | Monteverde & Associates PC
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Whitelogolarge.jpg
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CELL, DBTX, CPRI, ESTE
August 21, 2023 17:32 ET | Monteverde & Associates PC
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
logo.png
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
June 27, 2023 07:15 ET | Arch Biopartners
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to...